387 related articles for article (PubMed ID: 24551591)
1. Syndecans as modulators and potential pharmacological targets in cancer progression.
Barbouri D; Afratis N; Gialeli C; Vynios DH; Theocharis AD; Karamanos NK
Front Oncol; 2014; 4():4. PubMed ID: 24551591
[TBL] [Abstract][Full Text] [Related]
2. Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities.
Agere SA; Kim EY; Akhtar N; Ahmed S
J Cell Physiol; 2018 Sep; 233(9):6346-6358. PubMed ID: 29226950
[TBL] [Abstract][Full Text] [Related]
3. Shed proteoglycans in tumor stroma.
Piperigkou Z; Mohr B; Karamanos N; Götte M
Cell Tissue Res; 2016 Sep; 365(3):643-55. PubMed ID: 27365088
[TBL] [Abstract][Full Text] [Related]
4. Syndecans and Enzymes for Heparan Sulfate Biosynthesis and Modification Differentially Correlate With Presence of Inflammatory Infiltrate in Periodontitis.
Duplancic R; Roguljic M; Puhar I; Vecek N; Dragun R; Vukojevic K; Saraga-Babic M; Kero D
Front Physiol; 2019; 10():1248. PubMed ID: 31611818
[TBL] [Abstract][Full Text] [Related]
5. Syndecans and Enzymes Involved in Heparan Sulfate Biosynthesis and Degradation Are Differentially Expressed During Human Odontogenesis.
Kero D; Bilandzija TS; Arapovic LL; Vukojevic K; Saraga-Babic M
Front Physiol; 2018; 9():732. PubMed ID: 29962964
[TBL] [Abstract][Full Text] [Related]
6. Heparan Sulfate in the Tumor Microenvironment.
Bartolini B; Caravà E; Caon I; Parnigoni A; Moretto P; Passi A; Vigetti D; Viola M; Karousou E
Adv Exp Med Biol; 2020; 1245():147-161. PubMed ID: 32266657
[TBL] [Abstract][Full Text] [Related]
7. The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.
Hammond E; Khurana A; Shridhar V; Dredge K
Front Oncol; 2014; 4():195. PubMed ID: 25105093
[TBL] [Abstract][Full Text] [Related]
8. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
9. Syndecans in heart fibrosis.
Lunde IG; Herum KM; Carlson CC; Christensen G
Cell Tissue Res; 2016 Sep; 365(3):539-52. PubMed ID: 27411689
[TBL] [Abstract][Full Text] [Related]
10. Single-molecule force spectroscopy reveals structural differences of heparan sulfate chains during binding to vitronectin.
Herman K; Zemła J; Ptak A; Lekka M
Phys Rev E; 2021 Aug; 104(2-1):024409. PubMed ID: 34525582
[TBL] [Abstract][Full Text] [Related]
11. Three-Dimensional Human Neural Stem Cell Models to Mimic Heparan Sulfate Proteoglycans and the Neural Niche.
Peall IW; Okolicsanyi RK; Griffiths LR; Haupt LM
Semin Thromb Hemost; 2021 Apr; 47(3):308-315. PubMed ID: 33794554
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2020 Aug; 178():114084. PubMed ID: 32526230
[TBL] [Abstract][Full Text] [Related]
13. Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans.
Fjeldstad K; Kolset SO
Curr Drug Targets; 2005 Sep; 6(6):665-82. PubMed ID: 16178800
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.
Sanderson RD; Yang Y; Kelly T; MacLeod V; Dai Y; Theus A
J Cell Biochem; 2005 Dec; 96(5):897-905. PubMed ID: 16149080
[TBL] [Abstract][Full Text] [Related]
15. Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.
Nagarajan A; Malvi P; Wajapeyee N
Front Endocrinol (Lausanne); 2018; 9():483. PubMed ID: 30197623
[TBL] [Abstract][Full Text] [Related]
16. Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling.
Lopes CC; Dietrich CP; Nader HB
Braz J Med Biol Res; 2006 Feb; 39(2):157-67. PubMed ID: 16470302
[TBL] [Abstract][Full Text] [Related]
17. Syndecans in Inflammation at a Glance.
Gopal S
Front Immunol; 2020; 11():227. PubMed ID: 32133006
[TBL] [Abstract][Full Text] [Related]
18. Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma.
Motta JM; Hassan H; Ibrahim SA
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980680
[TBL] [Abstract][Full Text] [Related]
19. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
Lanzi C; Zaffaroni N; Cassinelli G
Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
[TBL] [Abstract][Full Text] [Related]
20. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains.
Kato M; Wang H; Bernfield M; Gallagher JT; Turnbull JE
J Biol Chem; 1994 Jul; 269(29):18881-90. PubMed ID: 8034644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
